Equity Insights May 7th: Warner Chilcott, Global Payments, Edwards Lifesciences, NetApp, Solazyme
Warner Chilcott plc (NASDAQ:WCRX): BofA/Merrill is assuming assuming a sale of Warner Chilcott and said if it does not happen there are other alternatives to drive shares higher. Shares are Buy rated with a $28 price target, up from $23.
Global Payments Inc. (NYSE:GPN): Baird views Global Payments shares as good value citing a limited financial impact to its recent credit card security breach. The firm also noted the company is sticking to its estimated number of cards that were breached which is is less than 1.5 million versus a recent article in the Wall Street Journal which estimated the number at possibly more than 7 million. Shares remain Buy rated with a $54 price target.
Edwards Lifesciences Corp. (NYSE:EW): Wells Fargo believes that an FDA panel is likely to recommend Edwards Lifesciences’ Sapien transcatheter aortic valve replacement for approval. The firm maintains an Outperform rating on the stock.
NetApp, Inc. (NASDAQ:NTAP): Pacific Crest believes that NetApp’s fundamentals are set to improve, while the stock is unlikely to drop significantly. The firm thinks that the shares could rise to $50 and it maintains an Outperform rating on the stock.
Solazyme Inc (NASDAQ:SZYM): Pacific Crest expects Solazyme to report good progress towards commercialization of its products on its upcoming earnings call. The firm thinks that the company is benefiting from positive supply/demand dynamics, and it reiterates an $18 target and Outperform rating.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.